Boehringer gets FDA's second 'national priority' approval Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

#BoehringerIngelheim has become the second company to get a product approved under the #FDA's #nationalpriorityvoucher programme, claiming the go-ahead for first-line use of #lungcancer drug #Hernexeos.

pharmaphorum.com/news/boehrin...

Boehringer Ingelheim's HERNEXEOS® Receives FDA Priority Award for Lung Cancer Treatment The FDA has awarded Boehringer Ingelheim's HERNEXEOS® a National Priority Voucher, accelerating its potential for treating advanced HER2-mutant lung cancer.

Boehringer Ingelheim's HERNEXEOS® Receives FDA Priority Award for Lung Cancer Treatment #USA #Boehringer_Ingelheim #Ridgefield #HERNEXEOS #HER2_lung_cancer

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role New trial data backs the use of Boehringer Ingelheim's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

Fresh from a return to #oncology with the FDA approval of #Hernexeos as a treatment for HER2-positive non-small cell #lungcancer (NSCLC), #BoehringerIngelheim is racing to expand its label, with #Bayer in hot pursuit.

pharmaphorum.com/news/esmo-bo...

Boehringer's HERNEXEOS® Shows Promising Results in Advanced HER2-Mutant NSCLC Patients Boehringer Ingelheim's HERNEXEOS® demonstrated a remarkable 77% response rate in treatment-naïve patients with advanced HER2-mutant NSCLC during the ESMO 2025 presentation.

Boehringer's HERNEXEOS® Shows Promising Results in Advanced HER2-Mutant NSCLC Patients #Germany #NSCLC #Ingelheim #HER2 #HERNEXEOS

Zongertinib (Hernexeos) Updates 2025: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Zongertinib is a selective TKI designed to target cancers driven by HER2 mutations. Learn more about its side effects, dosage, expectations.

Zongertinib (Hernexeos) Updates 2025: Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/zonger...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Zongertinib #Hernexeos #LungCancer #NSCLC

Boehringer Ingelheim's HERNEXEOS® Receives Breakthrough Designation for NSCLC The FDA has granted Breakthrough Therapy Designation to HERNEXEOS® for first-line treatment in advanced NSCLC, marking a significant advancement in cancer care.

Boehringer Ingelheim's HERNEXEOS® Receives Breakthrough Designation for NSCLC #United_States #Boehringer_Ingelheim #NSCLC #Ridgefield #HERNEXEOS

#BoehringerIngelheim's bid to return to the #oncology arena has been achieved with an FDA approval for #Hernexeos, a new, targeted treatment for non-small cell lung cancer (#NSCLC).

pharmaphorum.com/news/boehrin...